Table 1.
Demographic characteristics, treatment results of all subjects
| Age (y)/Gender | Presenting complaint | Ocular diagnosis | Systemic disease | Treatment | Initial BCVA (R/L) | Final BCVA (R/L) | Follow-up (m) | |
|---|---|---|---|---|---|---|---|---|
| 1 | 52/M | OU blurred vision | OU retrobulbar neuritis | MS | UR | 0.1/0.08 | UR | 2 |
| 2 | 49/M | OD blurred vision | OU choroidoretinitis | - | Pen 24 MUI iv d for 2 w; BPen, 2.4 MUI im d for 3 w | 0.3/0.6 | UR | 4 |
| 3 | 61/F | OU Blurred vision | OU choroidoretinitis; OS BRVO; OS VH | DM | Pen 24 MUI iv d for 2 w; BPen, 2.4 MUI im d for 3 w | 0.4/0.7 | 0.4/0.15 | 2 |
| 4 | 48/F | OU Blurred vision | OU choroidoretinitis; OU cataract | LN | Ceftriaxone 2 g iv d for 2 w; BPen, 2.4 MUI im d for 3 w | 0.05/0.4 | 1.0/0.8 | 22 |
| 5 | 52/M | OU Blurred vision, redness | OU papillioedema | HP | Ceftriaxone 2 g iv d for 2 w; BPen, 2.4 MUI im d for 3 w | 0.3/0.4 | 0.8/0.8 | 3 |
| 6 | 56/M | OS esotropia | OU CSCR; neurosyphilis; Argyll-Rovertson pupil | - | Ceftriaxone 2 g iv d for 2 w; BPen, 2.4 MUI im d for 3 w | 0.6/0.2 | UR | 1 |
| 7 | 55/M | OS blurred vision | OS papillioedema | - | BPen, 2.4 MUI im d for 3 w | 1.0/1.0 | 1.0/1.0 | 4 |
| 8 | 52/M | OU blurred vision | OU panuveitis; deafness | HIV+ | BPen, 2.4 MUI im d for 3 w | UR | UR | Transfers |
| 9 | 47/F | OS blurred vision | OS choroidoretinitis; OU DR | DM | Ceftriaxone 2 g iv d for 2 w; BPen, 2.4 MUI im d for 3 w | 0.8/0.5 | 0.8/0.6 | 3 |
| 10 | 44/F | OD blurred vision | OU choroidoretinitis | - | Ceftriaxone 2 g iv d for 2 w; BPen, 2.4 MUI im d for 3 w | 0.2/1.2 | 0.8/1.2 | 5 |
| 11 | 37/F | OD redness; blurred vision | OD anterior uveitis | HLA-B27 positive | BPen, 2.4 MUI im d for 3 w | 0.3/0.5 | 1.0/1.0 | 1 |
| 12 | 51/M | OD shadow float | OD choroidoretinitis | - | Ceftriaxone 2 g iv d for 2 w; BPen, 2.4 MUI im d for 3 w | 0.15/0.8 | 0.8/0.8 | 1 |
| 13 | 50/F | OS blurred vision | OS choroidoretinitis | - | Doxycycline 2.0 g P.Od for 30 d | 0.6/0.1 | 0.8/0.5 | 2 |
BCVA: best corrected visual acuity; R: right eye; L: left eye; BRVO: branch retinal vein occlusion; VH: vitreous hemorrhage; CSCR: chronic central serous chorioretinopathy; DR: diabetic retinopathy; LN: lupus nephritis; DM: diabetes mellitus; HP: hypertension; HIV: Human Immunodeficiency Virus; MS: multiple sclerosis; BPen: benzathine penicillin; Pen: aqueous penicillin G; AZM: azithromycin; UR: unrecorded.